Inventor · disambiguated record
Adel Moussa
Also filed as: MOUSSA ADEL · MOUSSA ADEL M · MOUSSA ADEL MOHAMED ALY ELSAYED
65 granted patents·40 pending applications·719 citations·filing 1997–2025
99Inventor score
Files withATEA PHARMACEUTICALS INC39IDENIX PHARMACEUTICALS INC17IDENIX PHARMACEUTICALS LLC12BIOTHEA PHARMA INC4CHILDRENS MEDICAL CENTER4
Top patents by PatentIndex Score
105 records- 0198US11738038B2Highly active compounds against COVID-19ATEA PHARMACEUTICALS INC·Filed 2021·Granted Aug 29, 2023·4 cites·38 claims
- 0298US10894804B2Nucleotide hemi-sulfate salt for the treatment of hepatitis C virusATEA PHARMACEUTICALS INC·Filed 2020·Granted Jan 19, 2021·10 cites·37 claims
- 0398US10875885B2β-d-2′-deoxy-2′-α-fluoro-2′-β-c-substituted-2-modified-n6-substituted purine nucleotides for HCV treatmentATEA PHARMACEUTICALS INC·Filed 2020·Granted Dec 29, 2020·9 cites·24 claims
- 0498US10874687B1Highly active compounds against COVID-19ATEA PHARMACEUTICALS INC·Filed 2020·Granted Dec 29, 2020·34 cites·20 claims
- 0598US10870672B2β-D-2′-deoxy-2′-α-fluoro-2′-β-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatmentATEA PHARMACEUTICALS INC·Filed 2020·Granted Dec 22, 2020·9 cites·36 claims
- 0698US10870673B2β-D-2′-deoxy-2′-α-fluoro-2′-β-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatmentATEA PHARMACEUTICALS INC·Filed 2020·Granted Dec 22, 2020·9 cites·34 claims
- 0798US10815266B2β-D-2′-deoxy-2′-α-fluoro-2′-β-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatmentATEA PHARMACEUTICALS INC·Filed 2019·Granted Oct 27, 2020·10 cites·2 claims
- 0898US10519186B2Nucleotide hemi-sulfate salt for the treatment of hepatitis C virusATEA PHARMACEUTICALS INC·Filed 2018·Granted Dec 31, 2019·24 cites·52 claims
- 0998US9828410B2β-D-2′-deoxy-2′-α-fluoro-2′-β-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatmentATEA PHARMACEUTICALS INC·Filed 2016·Granted Nov 28, 2017·28 cites·3 claims
- 1098US9211300B24′-fluoro nucleosides for the treatment of HCVIDENIX PHARMACEUTICALS INC·Filed 2013·Granted Dec 15, 2015·66 cites·23 claims
- 1197US12006340B2Nucleotide hemi-sulfate salt for the treatment of hepatitis c virusATEA PHARMACEUTICALS INC·Filed 2023·Granted Jun 11, 2024·2 cites·15 claims
- 1297US11813278B2Highly active compounds against COVID-19ATEA PHARMACEUTICALS INC·Filed 2021·Granted Nov 14, 2023·3 cites·37 claims
- 1397US11707480B2Highly active compounds against COVID-19ATEA PHARMACEUTICALS INC·Filed 2020·Granted Jul 25, 2023·3 cites·8 claims
- 1497US10239911B2Beta-D-2′-deoxy-2′-alpha-fluoro-2′-beta-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatmentATEA PHARMACEUTICALS INC·Filed 2018·Granted Mar 26, 2019·18 cites·24 claims
- 1597US10005811B2β-D-2′-deoxy-2′-α-fluoro-2′β-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatmentATEA PHARMACEUTICALS INC·Filed 2017·Granted Jun 26, 2018·19 cites·22 claims
- 1697US10000523B2β-D-2′-deoxy-2′-α-fluoro-2′-β-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatmentATEA PHARMACEUTICALS INC·Filed 2017·Granted Jun 19, 2018·20 cites·30 claims
- 1797US9187515B22′,4′-fluoro nucleosides for the treatment of HCVIDENIX PHARMACEUTICALS INC·Filed 2014·Granted Nov 17, 2015·51 cites·16 claims
- 1896US12226429B2Highly active compounds against COVID-19ATEA PHARMACEUTICALS INC·Filed 2023·Granted Feb 18, 2025·1 cites·17 claims
- 1996US12084473B2β-D-2′-deoxy-2′-α-fluoro-2′-β-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatmentATEA PHARMACEUTICALS INC·Filed 2023·Granted Sep 10, 2024·1 cites·29 claims
- 2096US10906928B2Nucleotide hemi-sulfate salt for the treatment of hepatitis C virusATEA PHARMACEUTICALS INC·Filed 2019·Granted Feb 2, 2021·10 cites·34 claims
- 2196US9309275B23′-deoxy nucleosides for the treatment of HCVIDENIX PHARMACEUTICALS INC·Filed 2014·Granted Apr 12, 2016·28 cites·24 claims
- 2296US9192621B2Esters and malonates of SATE prodrugsIDENIX PHARMACEUTICALS LLC·Filed 2013·Granted Nov 24, 2015·32 cites·22 claims
- 2396US9109001B23′,5′-cyclic phosphoramidate prodrugs for HCV infectionIDENIX PHARMACEUTICALS INC·Filed 2013·Granted Aug 18, 2015·60 cites·28 claims
- 2495US12134588B2Crystalline epinephrine malonate saltBIOTHEA PHARMA INC·Filed 2022·Granted Nov 5, 2024·3 cites·20 claims
- 2595US11975016B22′-substituted-N6-substituted purine nucleotides for RNA virus treatmentATEA PHARMACEUTICALS INC·Filed 2021·Granted May 7, 2024·2 cites·26 claims
- 2693US10946033B22′-substituted-N6-substituted purine nucleotides for RNA virus treatmentATEA PHARMACEUTICALS INC·Filed 2019·Granted Mar 16, 2021·6 cites·23 claims
- 2793US9339541B2Thiophosphate nucleosides for the treatment of HCVIDENIX PHARMACEUTICALS INC·Filed 2014·Granted May 17, 2016·36 cites·20 claims
- 2892US2025243235A1Beta-D-2'-DEOXY-2'-alpha-FLUORO-2'-Beta-C-SUBSTITUTED-2-MODIFIED-N6- SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENTATEA PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 2991US7781576B2Process for preparing a synthetic intermediate for preparation of branched nucleosidesIDENIX PHARMACEUTICALS INC·Filed 2006·Granted Aug 24, 2010·29 cites·38 claims
- 3089US11690860B2Treatment of HCV infected patients with cirrhosisATEA PHARMACEUTICALS INC·Filed 2020·Granted Jul 4, 2023·4 cites·37 claims
- 3189US10995059B2Crystalline epinephrine malonate saltBIOTHEA PHARMA INC·Filed 2019·Granted May 4, 2021·2 cites·15 claims
- 3288US10202412B2β-D-2′-deoxy-2′-substituted-4′-substituted-2-substituted-N6-substituted-6-aminopurinenucleotides for the treatment of paramyxovirus and orthomyxovirus infectionsATEA PHARMACEUTICALS INC·Filed 2017·Granted Feb 12, 2019·4 cites·20 claims
- 3387US7598373B2Process for the production of 2-C-methyl-D-ribonolactoneIDENIX PHARMACEUTICALS INC·Filed 2003·Granted Oct 6, 2009·43 cites·30 claims
- 3485US6028103ATriaryl methane compounds and analogues thereof useful for the treatment or prevention of sickle cell disease or diseases characterized by abnormal cell proliferationCHILDRENS MEDICAL CENTER·Filed 1997·Granted Feb 22, 2000·36 cites·42 claims
- 3584US12392619B2Vehicle localization system and methodPROFOUND POSITIONING INC·Filed 2021·Granted Aug 19, 2025·2 cites·17 claims
- 3684US2025051262A1Crystalline epinephrine malonate saltBIOTHEA PHARMA INC·Filed 2024·Application pending·0 cites
- 3783US8093379B2Macrocyclic serine protease inhibitorsMOUSSA ADEL·Filed 2009·Granted Jan 10, 2012·16 cites·18 claims
- 3879US7960428B2Enantiomerically pure phosphoindoles as HIV inhibitorsIDENIX PHARMACEUTICALS INC·Filed 2007·Granted Jun 14, 2011·3 cites·42 claims
- 3979US6462221B1Synthesis of nitroalcohol diastereomersJOHNSON MATTHEY PHARMACEUTICAL·Filed 2000·Granted Oct 8, 2002·9 cites·12 claims
- 4079US2022267366A1Beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substituted-2-modified-n6-substituted purine nucleotides for hcv treatmentATEA PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 4178US11505521B2Crystalline epinephrine malonate saltBIOTHEA PHARMA INC·Filed 2021·Granted Nov 22, 2022·0 cites·11 claims
- 4277US10251903B2Process for making nucleoside phosphoramidate compoundsMERCK SHARP & DOHME·Filed 2015·Granted Apr 9, 2019·2 cites·8 claims
- 4377US2021277045A1Nucleotide hemi-sulfate salt for the treatment of hepatitis c virusATEA PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 4476US2021009628A1Beta-D-2'-DEOXY-2'-Alpha-FLUORO-2'-Beta-C-SUBSTITUTED-2-MODIFIED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENTATEA PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 4575US12458656B2Advantageous anti-HCV combination therapyATEA PHARMACEUTICALS INC·Filed 2025·Granted Nov 4, 2025·0 cites·20 claims
- 4675US6331564B1Use of triaryl methane compounds for inhibiting unwanted cellular proliferation associated with inflammatory diseaseION PHARMACEUTICALS INC·Filed 1998·Granted Dec 18, 2001·43 cites·13 claims
- 4775US2021087217A1Nucleotide hemi-sulfate salt for the treatment of hepatitis c virusATEA PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 4874US2023365611A1Advantageous morphic form of at-527 hemi-sulfate saltATEA PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 4974US2024148770A1Advantageous anti-hcv combination therapyATEA PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 5073US10683321B24′-or nucleosides for the treatment of HCVIDENIX PHARMACEUTICALS LLC·Filed 2014·Granted Jun 16, 2020·2 cites·17 claims
Showing the top 50 of 105 patent records by PatentIndex Score.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →